A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus

Gene Therapy

Volumn 10, Issue 17, 2003, Pages 1458-1464

  Fu, X ^a,b   Meng, F ^a   Tao, L ^a,b   Jin, A ^a   Zhang, X ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Herpes simplex virus; Oncolytic; Strict late promoter; Tumor selective; UL38

Indexed keywords

ALKALINE PHOSPHATASE; ONCOLYTIC VIRUS; PLASMID DNA; VIRUS DNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIVISION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA REPLICATION; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TARGET CELL; TISSUE SPECIFICITY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS REPLICATION;

ALKALINE PHOSPHATASE; ANIMALS; CERCOPITHECUS AETHIOPS; CHEMILUMINESCENT MEASUREMENTS; DNA, VIRAL; FEMALE; GENE THERAPY; GENETIC ENGINEERING; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; PROMOTER REGIONS (GENETICS); SIMPLEXVIRUS; TRANSFECTION; TUMOR CELLS, CULTURED; VERO CELLS; VIRUS REPLICATION;

ANIMALIA; CYTOMEGALOVIRUS; DNA VIRUSES; SIMPLEXVIRUS;

EID: 0038278679     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302029     Document Type: Article

References (32)

1. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88: 8039-8043.
2. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.
3. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341.
4. Tanaka S et al. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther 2000; 7: 1241-1250.
5. Schuur ER et al. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996; 271: 7043-7051.
6. Koga S et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000; 11: 1397-1406.
7. Babiss LE, Friedman JM, Darnell JE. Cellular promoters incorporated into the adenovirus genome. Effect of viral DNA replication on endogenous and exogenous gene transcription. J Mol Biol 1987; 193: 643-650.
8. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science 1996; 274: 373-376.
9. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
10. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
11. Wagner EK, Guzowski JF, Singh J. Transcription of the herpes simplex virus genome during productive and latent infection. Prog Nucleic Acid Res Mol Biol 1995; 51: 123-165.
12. Holland LE, Anderson KP, Shipman Jr C, Wagner EK. Viral DNA synthesis is required for the efficient expression of specific herpes simplex virus type 1 mRNA species. Virology 1980; 101: 10-24.
13. Flanagan WM et al. Analysis of the herpes simplex virus type 1 promoter controlling the expression of UL38, a true late gene involved in capsid assembly. J Virol 1991; 65: 769-786.
14. Johnson PA, Everett RD. DNA replication is required for abundant expression of a plasmid-borne late US11 gene of herpes simplex virus type 1. Nucleic Acids Res 1986; 14: 3609-3625.
15. Guzowski JF, Wagner EK. Mutational analysis of the herpes simplex virus type 1 strict late UL38 promoter/leader reveals two regions critical in transcriptional regulation. J Virol 1993; 67: 5098-5108.
16. Guzowski JF, Singh J, Wagner EK. Transcriptional activation of the herpes simplex virus type 1 UL38 promoter conferred by the cis-acting downstream activation sequence is mediated by a cellular transcription factor. J Virol 1994; 68: 7774-7789.
17. Goodart SA, Guzowski JF, Rice MK, Wagner EK. Effect of genomic location on expression of beta-galactosidase mRNA controlled by the herpes simplex virus type 1 UL38 promoter. J Virol 1992; 66: 2973-2981.
18. Saeki Y et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9: 2787-2794.
19. Herrlinger U et al. HSV-1 infected cell proteins influence tetracycline-regulated transgene expression. J Gene Med 2000; 2: 379-389.
20. Schang LM, Phillips J, Schaffer PA. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol 1998; 72: 5626-5637.
21. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859-866.
22. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
23. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525-526.
24. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306-2312.
25. Todryk S et al. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999; 10: 2757-2768.
26. Bennett JJ et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000; 78: 166-174.
27. Schellingerhout D et al. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543-1549.
28. Wood M et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999; 6: 367-372.
29. Huard J, Goins WF, Glorioso JC. Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Therapy 1995; 2: 385-392.
30. Huard J et al. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996; 70: 8117-8123.
31. Shenk T. Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology. Lippincott Williams & Wilkins: Philadelphia, 1996, pp. 2111-2148.
32. Hawkins LK, Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Therapy 2001; 8: 1142-1148.